
Cheryl A Hillery

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2994936/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Transient receptor potential vanilloid 1 mediates pain in mice with severe sickle cell disease. Blood, 2011, 118, 3376-3383.	1.4	133
2	Patients with sickle cell disease have increased sensitivity to cold and heat. American Journal of Hematology, 2013, 88, 37-43.	4.1	127
3	Pathology of Berkeley sickle cell mice: similarities and differences with human sickle cell disease. Blood, 2006, 107, 1651-1658.	1.4	123
4	Pathophysiology of Stroke in Sickle Cell Disease. Microcirculation, 2004, 11, 195-208.	1.8	74
5	Cold hypersensitivity increases with age in mice with sickle cell disease. Pain, 2014, 155, 2476-2485.	4.2	54
6	Sickle cell disease increases high mobility group box 1: a novel mechanism of inflammation. Blood, 2014, 124, 3978-3981.	1.4	48
7	Circulating membrane-derived microvesicles in redox biology. Free Radical Biology and Medicine, 2014, 73, 214-228.	2.9	40
8	Inhibition of myeloperoxidase decreases vascular oxidative stress and increases vasodilatation in sickle cell disease mice. Journal of Lipid Research, 2013, 54, 3009-3015.	4.2	37
9	Determining the longitudinal validity and meaningful differences in HRQL of the PedsQLâ,,¢ Sickle Cell Disease Module. Health and Quality of Life Outcomes, 2017, 15, 124.	2.4	26
10	Chemokine (c-c motif) receptor 2 mediates mechanical and cold hypersensitivity in sickle cell disease mice. Pain, 2018, 159, 1652-1663.	4.2	25
11	Dietary supplementation with docosahexanoic acid (DHA) increases red blood cell membrane flexibility in mice with sickle cell disease. Blood Cells, Molecules, and Diseases, 2015, 54, 183-188.	1.4	23
12	IL-18 mediates sickle cell cardiomyopathy and ventricular arrhythmias. Blood, 2021, 137, 1208-1218.	1.4	22
13	Anion Exchange HPLC Isolation of High-Density Lipoprotein (HDL) and On-Line Estimation of Proinflammatory HDL. PLoS ONE, 2014, 9, e91089.	2.5	14
14	Redox signaling in sickle cell disease. Current Opinion in Physiology, 2019, 9, 26-33.	1.8	14
15	Impaired Bile Secretion Promotes Hepatobiliary Injury in Sickle Cell Disease. Hepatology, 2020, 72, 2165-2181.	7.3	12
16	Tissue Factor Deficiency Decreases Sickle Cell-Induced Vascular Stasis in a Hematopoietic Stem Cell Transplant Model of Murine Sickle Cell Disease Blood, 2004, 104, 236-236.	1.4	11
17	Characterization of a mouse model of sickle cell trait: parallels to human trait and a novel finding of cutaneous sensitization. British Journal of Haematology, 2017, 179, 657-666.	2.5	8
18	The Protein C Pathway in Human and Murine Sickle Cell Disease: Alterations in Protein C, Thrombomodulin (TM), and Endothelial Protein C Receptor (EPCR) at Baseline and during Acute Vaso-Occlusion. Blood, 2008, 112, 538-538.	1.4	8

CHERYL A HILLERY

#	Article	IF	CITATIONS
19	Low Molecular Weight Heparin Reduces sVCAM-1 and Lung Congestion In a Murine Model of Sickle Cell Disease. Blood, 2010, 116, 1635-1635.	1.4	4
20	A Novel Hemoglobin-Binding Agent Reduces Plasma Free Hemoglobin and Partially Improves Vascular Function In Murine Hemolytic Anemia. Blood, 2010, 116, 267-267.	1.4	4
21	Genetic Influence on the Systems Biology of Sickle Stroke Risk Detected by Endothelial Gene Expression Blood, 2005, 106, 73-73.	1.4	3
22	The chicken or the egg? Tissue factor and inflammation in sickle cell disease. Blood, 2004, 104, 595-596.	1.4	2
23	Patients with Sickle Cell Disease Have Increased Sensitivity to Cold and Heat Stimuli, 2. Blood, 2011, 118, 2116-2116.	1.4	2
24	Evidence for Transient Acute Liver Injury in Mouse Models of Sickle Cell Disease during Steady State Health. Blood, 2014, 124, 1373-1373.	1.4	2
25	Reciprocal binding of xanthine oxidase and myeloperoxidase with ApoAâ€l correlates with HDL anti―and proâ€inflammatory properties. FASEB Journal, 2006, 20, A198.	0.5	2
26	Desmopressin and Epsilon Amino-Caproic Acid (EACA) in Adenotonsillectomy (T & A): Are We Under-Treating Patients with Mild Type 1 von Willebrand Disease (VWD) and Mild Platelet Function Defects (PFD)? Blood, 2004, 104, 1024-1024.	1.4	0
27	AMP Deaminase Activation Contributes to Accelerated Adenine Nucleotide Pool Depletion during Periods of Energy Imbalance in Sickle Cell Erythrocytes Blood, 2005, 106, 1671-1671.	1.4	Ο
28	Phase I Study of Combination Treatment with Hydroxyurea and Magnesium Pidolate in Children with Sickle Cell Anemia Blood, 2006, 108, 686-686.	1.4	0
29	Modifications of the Coagulation System Alter Inflammation in Murine Sickle Cell Disease Blood, 2006, 108, 1242-1242.	1.4	Ο
30	Vascular Dysfunction in Murine Models of Hemolytic Anemia Blood, 2007, 110, 846-846.	1.4	0
31	Proinflammatory Lipids in Sickle Cell Disease-Associated Pulmonary Hypertension Blood, 2007, 110, 3801-3801.	1.4	Ο
32	A Novel Hemoglobin Binding Peptide Increases Intracellular Heme and Potentiates Hemoglobin-Induced HO-1 Levels in Endothelial Cells. Blood, 2011, 118, 1065-1065.	1.4	0
33	The Neuropeptide Substance P Is Elevated in Patients with Sickle Cell Disease. Blood, 2015, 126, 2190-2190.	1.4	Ο
34	HMCB1 As a Novel Platelet Agonist That Acts Synergistically with ADP to Activate Platelets in Sickle Cell Disease. Blood, 2018, 132, 1073-1073.	1.4	0
35	Circulating Neutrophil Extracellular Traps in the Pathogenesis of Acute Chest Syndrome of Sickle Cell Disease. Blood, 2019, 134, 3556-3556.	1.4	0
36	HMGB1-Mediated Platelet Activation Is Independent of Platelet Mitochondrial Reactive Oxygen Species Generation. Blood, 2020, 136, 6-6.	1.4	0

#	Article	IF	CITATIONS
37	A Pilot Study to Evaluate the Feasibility of Anti-Fibrinolytic Agents in Reducing Hemorrhagic Complications in Pediatric Patients with Thrombocytopenia. Blood, 2020, 136, 3-3.	1.4	0